At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Michael Stumvoll discusses the latest data from the VERIFY study.
Questions
1. What is the rationale for very early combination treatment with vildagliptin‐metformin in patients with newly diagnosed type 2 diabetes? (0:05)
2. How does the patient population in the VERIFY study differ from those in previous intervention studies? (1:00)
3. Could you tell us a little about the aims and design of the VERIFY study? (2:45)
4. What were the major efficacy and safety findings of this study? (4:27)
5. What are the implications of these findings for clinical practice? (6:00)
Michael Stumvoll has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
